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Abstract
Background: Several studies have investigated the effects of cardiac resynchronization therapy (CRT) 
on heart failure (HF), but none have evaluated the pathophysiological pathways involved in a single 
group of patients. Therefore, this study aims to assess the long-term effects of CRT on six different patho-
physiological pathways involved in the process of HF by the use of surrogate biomarkers. 
Methods: In a group 44 patients with HF, six groups of biomarkers were measured, both at baseline 
and 1 year after CRT implantation: inflammation (interleukin [IL]-4, IL-6, tumor necrosis fac-
tor [TNF]-a, high sensitive C-reactive protein [hsCRP]); oxidative stress (myeloperoxidase [MPO], 
oxidized low-density lipoprotein [oxLDL], uric acid); extracellular matrix (ECM) remodeling (matrix 
metalloproteinase [MMP]-2 and -9, galectin-3, procollagen III N-terminal propeptide [prokol-3NT]); 
neurohormonal pathways (endothelin-1, chromogranin-A); myocyte injury (troponin T, creatine kinase 
MB fraction [CK-MB]), myocyte stress (B-type natriuretic peptide [BNP]). CRT responders were de-
fined as patients with ≥ 15% reduction in left ventricular end-systolic volume at 12 months post-CRT.
Results: At 1-year follow-up, 72.7% (n = 32) of the patients were categorized as CRT responders. In these 
patients, the levels of IL-6, MPO, oxLDL, MMP-2, galectin-3, troponin T, and BNP were significantly 
reduced as compared to baseline values. While the biomarkers for myocyte stress (effect size = 0.357;  
p = 0.001), ECM remodeling (effect size = 0.343; p = 0.015) and oxidative stress (effect size = 0.247; 
p = 0.039) showed a significant change in the CRT responders during follow-up, the biomarkers for 
other pathophysiological pathways did not show a significant alteration. 
Conclusions: In the present study, a significant reduction was only observed in the biomarkers of myo-
cardial stress, ECM remodeling, and oxidative stress among all the CRT responder subjects. (Cardiol J  
2018; 25, 1: 42–51)
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Introduction
Heart failure (HF) is a progressive, chronic 
myocardial disorder involving various pathophysi-
ological pathways. It has recently been reported 
that six major pathways are involved, both in the 
development and the progression of HF [1]. Various 
management strategies including medical treat-
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ment and/or device implantation are aimed at either 
slowing down or reversing the disease process. 
Cardiac resynchronization therapy (CRT) is a valu-
able interventional therapeutic option in patients 
with systolic HF and left ventricular (LV) conduc-
tion disturbances, as it decreases the chances of 
both morbidity as well as mortality [2, 3]. Yet, up 
to 30–40% of the patients do not benefit from CRT 
implantation for several reasons [4, 5]. Although 
several studies using circulating biomarkers have 
been carried out to identify patient responsiveness 
to CRT [6–10], none could assess all the predefined 
pathophysiological pathways as a whole in the same 
patient population. Hence, the aim undertaken was 
to evaluate the relationship of CRT responsiveness 
with six different pathophysiological pathways of 
HF using surrogate biomarkers.
Methods
A total of 44 patients diagnosed with systolic 
HF, who underwent CRT implantation were in-
cluded in the study. The inclusion criteria were as 
follows: New York Heart Association (NYHA) class 
II–III symptoms despite optimal tolerable medical 
therapy, LV ejection fraction of ≤ 35%, and a QRS 
duration of > 120 ms either resulting from bundle 
branch block or intraventricular conduction delay. 
All subjects included in the study had to meet the 
inclusion criteria. Patients were excluded if they 
had atrial fibrillation (AF), acute or chronic inflam-
matory or infectious disease, recent (≤ 30 days) 
clinical diagnosis of acute coronary syndrome, 
acute decompensated HF, or had recently (< 6 
months) undergone a coronary revascularization 
procedure or a coronary by-pass surgery. The 
recorded baseline characteristics included patient 
demographics, QRS duration, etiology of cardio-
myopathy, medical history in relation to hyperten-
sion, diabetes, smoking, AF, and the use of the 
medications prescribed including beta-blockers, 
angiotensin-converting enzyme inhibitors, spirono-
lactone, digoxin, and diuretics. The study protocol 
was approved by the Ethics Committee. Written 
informed consent was obtained from all patients. 
Serial echocardiography was performed at both 
times, before and after CRT implantation in order 
to assess the degree of LV reverse remodeling 
and changes in cardiac function. LV end-systolic 
volume, LV end-diastolic volume, and ejection 
fraction were assessed using Simpson’s equation. 
The severity of mitral regurgitation was graded 
semi-quantitatively by color flow Doppler in the 
conventional parasternal long axis and by the 
images of the apical 4-chambers. Living patients 
were classified as CRT responders if they showed 
a ≥ 15% decrease in LV end-systolic volume (com-
pared to baseline) at the 12-month follow-up [11].
The LV lead was placed in the coronary sinus 
in order to achieve permanent epicardial stimula-
tion as described earlier [12]. CRT device and lead 
placements were accomplished in all the subjects 
without major complications (Medtronic, St. Paul, 
MN, USA and Biotronik, Berlin, Germany). The 
pacing mode was set at DDD which is programmed 
to maximize biventricular pacing, and the atrioven-
tricular and interventricular delays were optimized 
using Doppler echocardiography. Coronary sinus 
lead position, pacing mode, and the programming 
of timing intervals were evaluated at 1, 3, 6, and 
12 months after CRT implantation.
Blood samples were obtained from the patients 
after a 30-min bed rest, both before CRT and at the 
12-month follow-up visit and were stored at −80°C 
until used. Biomarkers that played a role in the patho-
genesis of HF were classified into six groups on the 
basis of the data obtained from previous studies [1]. 
The biomarkers that were assessed included interleu-
kin (IL)-4 (BMS225INST, Bendermed, Austria), IL-6 
(BMS213INS, Bendermed, Austria), tumor necrosis 
factor-alpha (TNF-a) (BMS223INST, Bendermed, 
Austria) and high-sensitive C-reactive protein 
(hsCRP) (EIA3954, DRG, Austria) for inflammation; 
oxidized low density lipoprotein (oxLDL) (K7810, 
Immune Diagnostic, Germany), myeloperoxidase 
(MPO) (K6631, Immune Diagnostic, Germany) and 
uric acid (routine) for oxidative stress; matrix metallo-
proteinase (MMP)-2 (ELH-MMP2-001, RayBiotech, 
Austria), MMP-9 (BMS2016/2, Bendermed, Austria), 
galectin-3 (BMS279/2, Bendermed, Austria) and 
procollagen III N-terminal propeptide (prokol--3NT) 
(E0573Hu, Uscnk, Austria) for extracellular remod-
eling; the neurohormones endothelin-1 (BI20052, 
BIOMEDICA, Canada) and chromogranin-A 
(RSCYK070R, Biovendor, Germany) by ELISA; 
troponin T (routine), creatine kinase MB fraction 
(CK-MB) (routine) for myocyte damage; and B-type 
natriuretic peptide (BNP) (routine) for myocyte 
stress. Blood samples from all patients were pro-
cessed according to instructions given by the manu-
facturer and were spectrophotometrically read on 
a SpectraMax M2 reader (Molecular Devices, Inc., 
Silicon Valley, CA, USA). 
Statistical analysis
All statistical analyses were performed us-
ing SPSS for Windows (ver. 20, IBM SPSS Inc., 
Chicago, IL). A p-value < 0.05 was considered to 
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be statistically significant. Quantitative variables 
with normal distribution were represented as mean 
± standard deviation and were analyzed by the 
Student t-test; whereas non-normally distributed 
variables were represented as median-interquartile 
range (IQR) and were analyzed using the two-
tailed Mann-Whitney U-test. Categorical data were 
expressed as proportions and compared using c2 
test. Initially, a univariate analysis was performed 
at baseline levels to investigate the association 
between biomarkers and the incidence of CRT-
-response. Subsequently, a multivariate analysis 
(backward LR) was also performed including those 
variables which had a p-value ≤ 0.25 in the univari-
ate analysis. The receiver-operating characteristic 
(ROC) curve was used to evaluate the performance 
of biomarker levels to predict the response to CRT. 
An optimal cut-off point was chosen as the sensitiv-
ity and specificity were maximized. The correla-
tion coefficients that were reported were based on 
a non-parametric method (Spearman rank). Time-
related changes in the biomarkers were analyzed by 
paired t test or Wilcoxon test. ‘Repeated measures 
two-way ANOVA’ was used to compare the change 
in biomarkers after CRT, both individually and as 
a group. Univariate and multivariate partial Eta 
values that indicate the degree of relationship be-
tween the disease status and changes in biomarkers 
were obtained from ANOVA tables, acquired after 
the analysis. The standard values thus obtained 
provide a quantitative assessment of the relation-
ship between the levels of biomarkers and disease 
status. This method enabled the evaluation of the 
effect of CRT on biomarker groups (Inflammation, 
Oxidative stress, Extracellular matrix remodeling, 
Neurohormones, Myocyte injury, Myocyte stress). 
Results
A total of 44 patients (mean age 61.6 ± 11.7 
years, 14 females) with successful implantation 
of biventricular implantable cardioverter defibril-
lators were included in the study. Out of these, 
32 (72.7%) patients were considered responders 
while the remaining 12 (27.2%) patients were non-
responders, as they did not respond to CRT. Out 
of the total patients included, left bundle branch 
block was present in all 32 (100%) responders 
and in 9 (75%) non-responders. Another baseline 
demographic, electrocardiographic and echocar-
diographic parameters were comparable in both 
responders and the non-responders (Table 1). 
Considerable left ventricle reverse remodeling was 
seen in all the responders with a mean decrease in 
LV end-systolic volume index from 75.96 ± 29.9 
mL/m2 to 58.56 ± 24.7 mL/m2 (p = 0.001) and 
a mean increase in LV ejection fraction from 
27.0 ± 5.47% at baseline to 35.44 ± 8.08% at 
12-month follow-up (p = 0.001). While the QRS width 
showed a significant decrease in the responders from 
162.5 (IQR 144–180) ms to 143 (IQR 130–158) ms 
(p = 0.001), a non-significant increase was ob-
served in the non-responders as well (145 [IQR 
128–166] ms to 164 [IQR 130–186] ms, p = 0.533). 
Table 1. Baseline characteristics of study participants.
All patients  
(n = 44)
Responders  
(n = 32)
Non-responders 
(n = 12)
P
Age [years] 61.93 ± 11.81 63.13 ± 10.4 59.0 ± 14.8 0.293
Gender (female) 15 (33.3%) 11 (34.4%) 4 (30.8%) 0.816
NYHA class 2.88 ± 0.26 2.83 ± 0.3 3.0 ± 0.0 0.003 
Hypertension 34 (75.6%) 22 (68.8%) 12 (92.3%) 0.096
Diabetes mellitus 10 (22.2%) 3 (9.4%) 7 (53.8%) 0.003 
Heart failure etiology: 0.307
Non-ischemic 27 (61.4%) 22 (68.8%) 5 (41.7%)
Ischemic 17 (38.6%) 10 (31.3%) 7 (58.3%)
QRS duration [ms] 159.82 ± 26.84 164.6 ± 26.6 148.0 ± 24.6 0.059
Left bundle branch block 41 (91.1%) 32 (100%) 9 (69.2%) 0.001
End-diastolic volume index [mL/m2] 105.56 ± 38.04 103.36 ± 36.48 111.43 ± 43.05 0.537
End-systolic volume index [mL/m2] 77.48 ± 30.13 75.96 ± 29.91 81.54 ± 66.58 0.590
Ejection fraction [%] 26.98 ± 4.79 27.0 ± 5.5 26.9 ± 2.6 0.950
Values are presented as mean ± standard deviation or number (percentage); NYHA — New York Heart Association
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Analysis of the responders showed that, at 
the 12-month follow-up visit, levels of IL-6, MPO, 
oxLDL, MMP-2, galectin-3, troponin T, and BNP 
were significantly lower than the baseline; while 
the levels of IL-4, hsCRP, TNF-a, uric acid, MMP-9, 
prokol-3NT, endothelin-1, chromogranin A and 
CK-MB did not show a significant change. On the 
other hand, in the non-responders, the levels of 
MPO and MMP-2 were lower; uric acid level was 
higher and the levels of IL-4, IL-6, hsCRP, TNF-a, 
oxLDL, MMP-9, prokol-3NT, galectin-3, endothe-
lin-1, chromogranin A, troponin T, CK-MB, and 
BNP did not show a significant change at 12-month 
follow-up (Table 2). 
Out of the pathways involved in the pathogen-
esis of HF, significant changes were observed in 
three of them, i.e. myocyte stress, extracellular 
matrix (ECM) remodeling, and oxidative stress, of 
the six pathways that were studied. At follow-up, no 
significant changes were seen in the inflammatory, 
myocyte injury, and neurohormonal pathways. On 
repeated measures, two-way ANOVA showed that 
the changes in myocyte stress markers had the 
greatest effect size (effect size = 0.357; p = 0.001) 
followed by changes in markers of ECM remodeling 
(effect size = 0.343; p = 0.015) and oxidative stress 
(effect size = 0.247; p = 0.039) (Table 3). 
In the present study, out of 44 patients in-
cluded, 33 (75%) were clinical responders (im-
provement NYHA class ≥ 1). When analysis was 
performed in the clinical responders on the basis 
of clinical improvement, a decrease in levels of 
IL-6, MPO, oxLDL, galectin-3, MMP-2, MMP-9, 
endothelin-1, troponin T, and BNP was found 
while levels of IL-4, TNF-a, hsCRP, uric acid, 
prokol-3NT, chromogranin A, and CK-MB did not 
show any change. Similar findings were obtained 
with ANOVA analysis, viz., surrogate biomarkers 
of oxidative stress, ECM remodeling, and myo-
cyte stress showed a significant improvement in 
clinical responder patients. In the study population, 
27 patients had non-ischemic etiology for HF. Of 
these, 22 (81.5%) were found to be responders. 
Biochemical analysis in the patients with HF 
due to nonischemic etiology revealed that levels 
of IL-6, TNF-a, MPO, MMP-2, galectin-3, and 
BNP decreased; while levels of IL-4, hsCRP, uric 
acid, oxLDL, MMP-9, prokol-3NT, endothelin-1, 
chromogranin A, troponin T and CK-MB levels 
showed no improvement. When the biomarkers 
were considered as a pathway group, a significant 
improvement was observed in oxidative stress, 
ECM remodeling, and myocyte stress biomarker 
groups (data not shown).
For the prediction of CRT response, MPO, 
uric acid, oxLDL, chromogranin A, and BNP were 
found to be potential covariates in the univariate 
analysis (MPO: odds ratio [OR] 0.999, 95% con-
fidence interval [CI] 0.998–1.001, p = 0.206; uric 
acid: OR 1.488, 95% CI 0.975–2.273, p = 0.066; 
oxLDL: OR 0.960, 95% CI 0.920–1.002, p = 0.059; 
chromogranin A: OR 0.997, 95% CI 0.993–1.001, 
p = 0.126; BNP: OR 0.998, 95% CI 0.997–0.999, 
p = 0.016, respectively). After adjustment for the 
covariates with multivariate regression analysis, 
it was found that preimplantation BNP and oxLDL 
were independent predictors of CRT response 
(BNP: OR 0.998, 95% CI 0.997–0.999, p = 0.042; 
oxLDL: OR 0.956, 95% CI 0.907–0.999, p = 0.049, 
respectively). The most sensitive BNP and oxLDL 
cut-off levels for CRT response determined by 
ROC analysis were 682 pg/mL and 37.5 ng/mL, 
respectively. In order to further explore the rela-
tionships between the investigated biomarkers, 
a detailed correlation analysis was performed 
(Table 4). Troponin T levels correlated significantly 
with uric acid (rho = 0.495, p = 0.001), MMP-2 
(rho = 0.425, p = 0.010), galectin-3 (rho = 0.329, 
p = 0.033), and BNP (rho = 0.397, p = 0.009). 
IL-4 levels correlated in turn with hsCRP (rho = 
= 0.321, p = 0.041), and inversely with CK-MB 
(rho = –0.330, p = 0.035). Furthermore, hsCRP 
levels correlated significantly with uric acid (rho = 
= 0.358, p = 0.025). MPO levels correlated signifi-
cantly with galectin-3 (rho = 0.310, p = 0.041). In 
addition, BNP and MMP-2 levels were found to be 
significantly correlated (rho = 0.457, p = 0.004).
Discussion
In the present study, it was found that CRT is 
associated with an improvement in the biomarkers 
of myocyte stress, ECM remodeling, and oxidative 
stress, besides having a beneficial effect on the 
clinical and echocardiographic parameters. The 
most prominent change was seen in the markers 
of myocyte stress, followed by those of oxida-
tive stress and ECM remodeling. However, the 
biomarkers of inflammation, neurohormones, and 
myocyte injury did not show a statistically signifi-
cant change. 
Cardiac remodeling mainly results in cardiac 
dysfunction. It involves a pathophysiological sub-
strate for its onset and progresses to ventricular 
dysfunction. Consequently, cellular and molecular 
changes occur, which result in a progressive loss of 
ventricular function and dilatation leading to QRS 
prolongation. QRS expansion leads to molecular 
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polarization and re-arrangement of myocardial 
blood [13, 14]. The studies on the pathogenesis 
of HF have shown that in the process of cardiac 
dysfunction, inflammation, oxidative stress, ECM 
remodeling, neurohormones, myocyte damage, and 
myocyte stress play a role [1, 15]. It is important 
to study the changes in the pathophysiological 
process after resynchronization between the ven-
tricular walls. 
Cardiac resynchronization therapy reduces 
BNP and troponin levels by decreasing intraven-
tricular pressure and myocardial wall tension [16]. 
Comprehensive investigations have been carried 
out on the biological role and the potential clini-
cal applications of the natriuretic peptides. Many 
studies have shown that a significant decrease in 
BNP levels occurs after CRT, resulting in a good 
prognosis [17]. The results obtained in this study 
are comparable to those of the previous studies. It 
has also been found that the positive effects of CRT 
on myocyte stress are accompanied by a decrease 
in BNP levels. Though a significant decrease was 
seen in myocyte stress, yet there were only limited 
changes seen in the biomarkers of myocyte damage 
after CRT. The results of the present study are con-
sistent with those of previous research which has 
shown that an increase in ventricular wall tension 
results in much lower subclinical myocardial dam-
age when compared to ischemic heart disease [18].
Ventricular remodeling plays a significant 
role in the progression to HF. The ECM provides 
a skeleton for myocytes and determines their 
size and shape. The ECM is a metabolically ac-
tive structure with a continuous turnover of its 
elements so that a dynamic balance between the 
synthesis and degradation of collagen is main-
tained. Myofibroblasts function to regulate collagen 
turnover and respond to stimuli like a mechanical 
stretch, wall stress, autocrine, and paracrine fac-
tors. The response of the myofibroblasts to these 
factors results in an imbalance between MMPs 
and their inhibitors, which is in turn associated 
with ventricular dysfunction and dilatation [19]. 
Any abnormality in collagen metabolism may also 
Table 3. Analysis of the changes in biomarkers after cardiac resynchronization therapy, one-by-one 
and as a group, by employing repeated measures of two-way analysis of variance.
Pathways and biomarkers Effect size (Partial Eta Squared) P 
Responders Non-responders Responders Non-responders
Inflammation 0.111 0.096 0.100 0.414
Interleukin-4 0.115 0.047 0.054 0.459
Interleukin-6 0.194 0.003 0.01 0.858
hsCRP 0.093 0.105 0.085 0.257
TNF-a 0.042 0.230 0.251 0.083
Oxidative stress 0.247 0.331 0.039 0.068
Myeloperoxidase 0.508 0.357 0.001 0.024
Uric acid 0.093 0.489 0.085 0.005
Oxidized LDL 0.141 0.147 0.031 0.175
Extracellular-matrix remodeling 0.343 0.358 0.015 0.060
MMP-2 0.677 0.637 0.001 0.001
MMP-9 0.125 0.148 0.044 0.174
Prokol-3NT 0.168 0.307 0.018 0.04
Galectin-3 0.402 0.342 0.001 0.028
Neurohormonal pathways 0.069 0.050 0.272 0.204
Endothelin-1 0.122 0.071 0.046 0.356
Chromogranin A 0.015 0.277 0.498 0.053
Myocyte injury 0.046 0.199 0.536 0.137
Troponin T 0.091 0.122 0.088 0.221
CK-MB 0.001 0.277 0.985 0.053
Myocyte stress (BNP) 0.357 0.088 0.001 0.303
BNP — B-type natriuretic peptide; CK-MB — creatine kinase MB fraction; hsCRP — high sensitive C-reactive protein; LDL — low density lipo-
protein; MMP — matrix metalloproteinase; Prokol-3NT — procollagen III N-terminal propeptide; TNF-a — tumor necrosis factor alpha
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prove to be deleterious to cardiac functions as the 
resultant fibrotic changes can result in impairment 
of ventricular function [20]. Cardiac synchroniza-
tion decreases the mechanical tension and stress 
imposed on the left ventricle. As the process of 
reverse remodeling begins, an improvement in 
ECM metabolism and a decrease in the levels of 
ECM remodeling markers (like galectin-3, prokol- 
-3NT, and MMPs) is also seen [21, 22]. In the pre-
sent study, a significant decrease was observed in 
the levels of MMP-9 and galectin-3. However, the 
changes in the levels of MMP-2 and procollagen 
were not significant. Some previous studies have 
also demonstrated that systemic MMP levels may 
not exactly reflect MMP metabolism in the cardiac 
muscle; while other studies have shown that an 
increase in collagen precursors may actually reflect 
reverse cardiac remodeling [23].
Oxidative stress results from an imbalance 
between the formations of reactive oxygen spe-
cies (ROS) and endogenous antioxidant defense 
mechanisms. The imbalance in oxidative metabo-
lism has deleterious effects on the progression to 
HF. Oxidative stress can damage cellular proteins 
and lead to myocyte apoptosis and necrosis. Since 
direct quantification of reactive oxygen species in 
humans is difficult, indirect markers of oxidative 
stress have been developed that include molecules 
like oxLDL, uric acid, and MPO. An increase in the 
level of plasma oxLDL in a peripheral blood sam-
ple may indicate an increase in ROS in the failing 
myocardium or in the poorly perfused peripheral 
muscles of patients with HF. Uric acid is a predictor 
of poor prognosis in patients with HF. During HF, 
the levels of circulating MPO increase and correlate 
with disease intensity [15, 24]. On the contrary, the 
improvements in the clinical status of patients and 
reverse remodeling after resynchronization therapy 
are associated with a decrease in oxidative stress 
[25, 26]. The levels of biomarkers indicating oxida-
tive stress were improved at the end of the follow-up 
period in the present study, which is consistent with 
these findings. Another significant finding is that 
the oxLDL and BNP were found to be independent 
predictors for CRT response. Since the present study 
is the first of its kind investigating the oxLDL in the 
CRT patients, the findings of this study form a base 
for further studies.
It has been established that HF is associated 
with systemic inflammation and that it involves the 
interplay between pro-inflammatory and inhibitory 
cytokines. It is hypothesized that CRT reduces 
inflammation and that it may be one of the several 
factors responsible for improving the symptoms of 
HF. However, the available literature reports con-
flicting results and suggests that the role of CRT 
in reducing inflammation is not uniform, rather it 
shows variations due to different interactions oc-
curring during the disease process [27, 28]. It was 
also found in the present study that no significant 
change occured in the levels of inflammatory bio-
markers, except in IL-6. 
It is well known that during HF the neurohor-
mones increase as a response to a vasoconstriction 
due to reduced peripheral flow, and this response 
results in further myocardial damage while also 
worsening cardiac functions [29]. Though the ef-
fect of neurohormones in the pathogenesis of HF 
was first identified more than 50 years ago, its role 
in dyssynchrony remains unclear [1]. When the 
power of contraction of the heart decreases, the 
resultant decline in peripheral circulation induces 
an increase in catecholamine and endothelin levels 
in order to restore circulation. Previous studies 
have demonstrated that increased endothelin-1 
levels are associated with both ventricular and vas-
cular fibrosis. The level of chromogranin-A, which 
increases circulation may be associated with neu-
roendocrine activation and to the clinical severity 
in patients with HF [29–31]. However, no decrease 
in levels of endothelin-1 and chromogranin-A 
after CRT implantation was found in the present 
study, suggesting that the optimal medical therapy, 
particularly the beta-blockers, may affect the con-
centration of neurohormones in patients with HF. 
Limitations of the study
This study had a few limitations, firstly, this 
was a small-sized preliminary and hypothesis gen-
erating study rather than a cause-effect association 
study. The small sample size especially poses dif-
ficulty in statistical analysis for the prediction of 
CRT response and the correlation between each 
biomarker. In addition, according to the current 
guidelines, class I recommendation has been in-
troduced for CRT in patients with QRS duration 
≥ 150 ms and this therapy is not recommended 
for the patients whose QRS duration is less than 
130  ms. However, only two-thirds of patients 
included in the present study met this criterion. 
Secondly, six pathophysiological pathways and 
more than 30 biomarkers are associated with both 
development and progression of HF. The pathways 
were investigated together in order to understand 
how they are affected by CRT therapy using a lim-
ited number of biomarkers. As the blood samples 
were obtained only at two points in time, i.e., at 
the time of initiation of the study and at 12-month 
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follow-up, it is also possible that some information 
on these markers may have been missed during 
the period in between. Thirdly, certain pathways 
are not independent but are interdependent. The 
inflammatory, oxidative and remodeling processes 
constitutes complex chemical reactions that in-
volve many molecules; therefore eliminating an in-
dividual variation among the circulating biomarkers 
is almost impossible. In addition, some biomarkers 
may also be indicative of multiple pathophysiologi-
cal pathways.
Conclusions
In the present study, a significant reduction 
was observed only in the biomarkers of myocar-
dial stress, ECM remodeling and oxidative stress 
among all the CRT responder subjects. Neverthe-
less, further large-scale studies are required to 
confirm the results of this preliminary, hypothesis 
generating study. 
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